

# DEPOSITARY RECEIPTS

## NEW DR ANNOUNCEMENT

February 12, 2016

### Implanet SA

Implanet is a medical technology company based in France. The Company is engaged in the manufacturing, marketing and commercial development of implants and medical devices used in orthopedic surgery. The Company's product range covers arthroscopy, knee and spinal products and includes prosthetic knees, spinal bracing systems, inter-somatic cages, pins, suture threads, screws and anchors, among others. The Company's flagship product, the JAZZ latest-generation implant, treats spinal pathologies requiring vertebral fusion surgery. The Company's Spine System provides immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion of the thoracic, lumbar and sacral spine.

<b>Effective Date:</b>	February 11, 2016
<b>Country of Incorporation:</b>	France
<b>Exchange:</b>	OTC
<b>Type of ADR Program:</b>	Sponsored - Level I
<b>Ticker Symbol:</b>	IMPZY
<b>CUSIP Number:</b>	45321V108
<b>Ratio (DR:ORD):</b>	1 : 2
<b>Underlying Share Description:</b>	Common
<b>Industry Classification:</b>	Pharma. & Biotech.
<b>Custodian(s) :</b>	BNP Paribas Securities Services

To learn more about ADRs and issuer programs, please call our marketing desks:

#### New York

Ravi Davis / Rick Maehr  
DR Broker Liaison  
adrdesk@bnymellon.com  
+1 212 815 2267

#### London

Jacek Jankowski  
DR Broker Liaison  
jacek.jankowski@bnymellon.com  
+44 207 163 7427

Depository Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contained herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.

DEPOSITARY RECEIPTS



BNY MELLON